<?xml version='1.0' encoding='utf-8'?>
<document id="23413998"><sentence text="Investigation of drug-drug interactions between clopidogrel and fluoxetine."><entity charOffset="48-59" id="DDI-PubMed.23413998.s1.e0" text="clopidogrel" /><entity charOffset="64-74" id="DDI-PubMed.23413998.s1.e1" text="fluoxetine" /><pair ddi="false" e1="DDI-PubMed.23413998.s1.e0" e2="DDI-PubMed.23413998.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23413998.s1.e0" e2="DDI-PubMed.23413998.s1.e1" /></sentence><sentence text="Drug-drug interactions may contribute to the variability of the response of clopidogrel"><entity charOffset="76-87" id="DDI-PubMed.23413998.s2.e0" text="clopidogrel" /></sentence><sentence text=" Several hypotheses have been proposed concerning the potential modification of clopidogrel pharmacokinetics and pharmacodynamics by fluoxetine"><entity charOffset="80-91" id="DDI-PubMed.23413998.s3.e0" text="clopidogrel" /><entity charOffset="133-143" id="DDI-PubMed.23413998.s3.e1" text="fluoxetine" /><pair ddi="false" e1="DDI-PubMed.23413998.s3.e0" e2="DDI-PubMed.23413998.s3.e0" /><pair ddi="false" e1="DDI-PubMed.23413998.s3.e0" e2="DDI-PubMed.23413998.s3.e1" /></sentence><sentence text=" This open-label crossover study assessed the effect of fluoxetine on the pharmacological activity of clopidogrel in healthy volunteers"><entity charOffset="56-66" id="DDI-PubMed.23413998.s4.e0" text="fluoxetine" /><entity charOffset="102-113" id="DDI-PubMed.23413998.s4.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.23413998.s4.e0" e2="DDI-PubMed.23413998.s4.e0" /><pair ddi="false" e1="DDI-PubMed.23413998.s4.e0" e2="DDI-PubMed.23413998.s4.e1" /></sentence><sentence text=" Eight healthy male volunteers received a single 600-mg loading dose of clopidogrel followed by 20 mg of fluoxetine on 4 days and then 20 mg of fluoxetine plus 600 mg of clopidogrel on the fifth day"><entity charOffset="72-83" id="DDI-PubMed.23413998.s5.e0" text="clopidogrel" /><entity charOffset="105-115" id="DDI-PubMed.23413998.s5.e1" text="fluoxetine" /><entity charOffset="144-154" id="DDI-PubMed.23413998.s5.e2" text="fluoxetine" /><entity charOffset="170-181" id="DDI-PubMed.23413998.s5.e3" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.23413998.s5.e0" e2="DDI-PubMed.23413998.s5.e0" /><pair ddi="false" e1="DDI-PubMed.23413998.s5.e0" e2="DDI-PubMed.23413998.s5.e1" /><pair ddi="false" e1="DDI-PubMed.23413998.s5.e0" e2="DDI-PubMed.23413998.s5.e2" /><pair ddi="false" e1="DDI-PubMed.23413998.s5.e0" e2="DDI-PubMed.23413998.s5.e3" /><pair ddi="false" e1="DDI-PubMed.23413998.s5.e1" e2="DDI-PubMed.23413998.s5.e1" /><pair ddi="false" e1="DDI-PubMed.23413998.s5.e1" e2="DDI-PubMed.23413998.s5.e2" /><pair ddi="false" e1="DDI-PubMed.23413998.s5.e1" e2="DDI-PubMed.23413998.s5.e3" /><pair ddi="false" e1="DDI-PubMed.23413998.s5.e2" e2="DDI-PubMed.23413998.s5.e2" /><pair ddi="false" e1="DDI-PubMed.23413998.s5.e2" e2="DDI-PubMed.23413998.s5.e3" /></sentence><sentence text=" Eleven blood samples were withdrawn after clopidogrel administration to determine plasma concentrations of clopidogrel active metabolite (CAM) and platelet function"><entity charOffset="43-54" id="DDI-PubMed.23413998.s6.e0" text="clopidogrel" /><entity charOffset="108-119" id="DDI-PubMed.23413998.s6.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.23413998.s6.e0" e2="DDI-PubMed.23413998.s6.e0" /><pair ddi="false" e1="DDI-PubMed.23413998.s6.e0" e2="DDI-PubMed.23413998.s6.e1" /></sentence><sentence text=" Platelet aggregation was measured by light transmittance aggregometry (LTA) and platelet reactivity index by flow cytometric vasodilator-stimulated phosphoprotein (VASP) analysis" /><sentence text=" The areas under the curve and maximum plasma concentrations of CAM were, respectively, 20" /><sentence text="6 and 25" /><sentence text="3% lower after co-administration of fluoxetine compared with administration of clopidogrel alone"><entity charOffset="36-46" id="DDI-PubMed.23413998.s10.e0" text="fluoxetine" /><entity charOffset="79-90" id="DDI-PubMed.23413998.s10.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.23413998.s10.e0" e2="DDI-PubMed.23413998.s10.e0" /><pair ddi="false" e1="DDI-PubMed.23413998.s10.e0" e2="DDI-PubMed.23413998.s10.e1" /></sentence><sentence text=" The percentage maximum platelet aggregation values in the presence of 5 μM and 10 μM adenosine diphosphate, measured by LTA, were, respectively, 13"><entity charOffset="86-107" id="DDI-PubMed.23413998.s11.e0" text="adenosine diphosphate" /></sentence><sentence text="9 and 22" /><sentence text="4% lower after fluoxetine co-administration"><entity charOffset="15-25" id="DDI-PubMed.23413998.s13.e0" text="fluoxetine" /></sentence><sentence text=" The platelet reactivity index measured by the flow cytometric VASP method was 36" /><sentence text="8% lower when clopidogrel was administered in conjunction with fluoxetine"><entity charOffset="14-25" id="DDI-PubMed.23413998.s15.e0" text="clopidogrel" /><entity charOffset="63-73" id="DDI-PubMed.23413998.s15.e1" text="fluoxetine" /><pair ddi="false" e1="DDI-PubMed.23413998.s15.e0" e2="DDI-PubMed.23413998.s15.e0" /><pair ddi="false" e1="DDI-PubMed.23413998.s15.e0" e2="DDI-PubMed.23413998.s15.e1" /></sentence><sentence text="" /></document>